Gauging Glaxo's Vaccine Value

Despite all the commotion at the FDA, some compounds in select therapeutic categories still have a fair chance of reaching the market. On Tuesday, GlaxoSmithKline (NYSE: GSK  ) received marketing approval for a combination children's vaccine.

This has been a good week for Glaxo's vaccine division. The approval of this combination diphtheria, tetanus, pertussis, and polio vaccine, called Kinrix, also comes at the same time that the U.S. Centers for Disease Control (CDC) recommended that children get treated with another of Glaxo's recently approved vaccines, Rotarix. The CDC also declared Rotarix equivalent to Merck's (NYSE: MRK  ) competing RotaTeq vaccine.

Vaccines and other compounds going through the FDA's Center for Biologics Evaluation and Research (CBER) haven't faced the same degree of regulatory-decision-delay insanity that is occurring at the agency's much more oft-used Center for Drug Evaluation and Research (CDER). CBER-approved vaccines and other therapeutic compounds were actually up in the first quarter this year, and they could rise again year over year for all of 2008, depending on whether some other compounds can squeeze past CBER review.

While they're not often discussed unless innovative game-changing vaccines like Merck and Glaxo's HPV vaccines arrive, vaccines have been a secret sauce behind the success of several of the pharmaceutical sector's largest drugmakers. Helping to prevent conditions like childhood diarrhea and polio may not be a drugmaker's sexiest roles, but vaccine sales have been brisk and growing rapidly in recent years.

Company

2007 vaccine sales

Year-over-year growth

GlaxoSmithKline

$4.0 billion

18%

Merck

$4.3 billion*

126%

Sanofi-Aventis (NYSE: SNY  )

$3.8 billion**

15%

Novartis (NYSE: NVS  )

$1.5 billion***

57%

*Excludes some partnership sales.
**At a 1 euro-to-$1.35 exchange rate.
***Includes some diagnostics sales as well.

Other drugmakers, like Novartis and AstraZeneca (NYSE: AZN  ) , have also seen the value in vaccine development. Both recently made multibillion-dollar acquisitions of new vaccine developers (Chiron for Novartis, and MedImmune for AstraZeneca).

Vaccines also have some innate competitive advantages compared to their traditional small-molecule drug counterparts, making them more resistant to competition over the long run and thus more valuable than traditional drugs. At the end of last year, Glaxo had 24 vaccines in clinical testing, and seven in phase 3 testing. Don't underestimate the power of vaccines to boost a drugmaker's bottom line, and drive significant growth over the long haul.

GlaxoSmithKline is an active Income Investor pick. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has an A+ disclosure policy.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 673659, ~/Articles/ArticleHandler.aspx, 11/21/2014 10:10:56 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,810.06 91.06 0.51%
S&P 500 2,063.50 10.75 0.52%
NASD 4,712.97 11.10 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/21/2014 4:03 PM
GSK $46.40 Up +0.02 +0.04%
GlaxoSmithKline CAPS Rating: ****
AZN $74.56 Up +0.35 +0.47%
AstraZeneca plc (A… CAPS Rating: ****
MRK $59.66 Up +0.28 +0.47%
Merck & Co., Inc. CAPS Rating: ****
NVS $94.98 Down -0.29 -0.30%
Novartis CAPS Rating: *****
SNY $47.15 Up +0.58 +1.25%
Sanofi (ADR) CAPS Rating: ****

Advertisement